CGON - CG Oncology, Inc. Common stock
CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company's investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones.
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase 3 trial in the first half of the year.
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.45 per share a year ago.
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026 Date: Tuesday, May 12, 2026Presentation Time: 10:40 AM – 11:10 AM PTLocation: Las Vegas, NV RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 20, 2026Presentation Time: 2:35 PM – 3:00 PM ETLocation: New York, NY Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com.
CG Oncology, Inc. (CGON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
JPMorgan Chase and Co. boosted its stake in CG Oncology, Inc. (NASDAQ: CGON) by 321.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 227,879 shares of the company's stock after buying an additional 173,785 shares during the period. JPMorgan
Kynam Capital sold 1,059,375 shares of CG Oncology in the fourth quarter; the estimated trade size was $43.84 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $41.50 million, reflecting both trading activity and price movement.
CG Oncology (NASDAQ: CGON - Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call
ArrowMark Colorado Holdings LLC cut its position in CG Oncology, Inc. (NASDAQ: CGON) by 12.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 257,230 shares of the company's stock after selling 35,776 shares during the quarter. ArrowMark Colorado Holdings
CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) and CG Oncology (NASDAQ: CGON - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares CollPlant Biotechnologies
CG Oncology (NASDAQ: CGON - Get Free Report) and Adhera Therapeutics (OTCMKTS:ATRX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Analyst Recommendations This is a summary of current
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders purchased 30,105 call options on the stock. This represents an increase of 3,313% compared to the average daily volume of 882 call options. Analyst Upgrades and Downgrades A number of equities research analysts have